全文获取类型
收费全文 | 193092篇 |
免费 | 33459篇 |
国内免费 | 2618篇 |
专业分类
耳鼻咽喉 | 5516篇 |
儿科学 | 6554篇 |
妇产科学 | 3569篇 |
基础医学 | 8898篇 |
口腔科学 | 2406篇 |
临床医学 | 30842篇 |
内科学 | 56258篇 |
皮肤病学 | 8235篇 |
神经病学 | 19219篇 |
特种医学 | 7737篇 |
外科学 | 46316篇 |
综合类 | 405篇 |
现状与发展 | 72篇 |
一般理论 | 19篇 |
预防医学 | 10206篇 |
眼科学 | 4067篇 |
药学 | 3666篇 |
1篇 | |
中国医学 | 91篇 |
肿瘤学 | 15092篇 |
出版年
2024年 | 736篇 |
2023年 | 5187篇 |
2022年 | 2130篇 |
2021年 | 4756篇 |
2020年 | 6939篇 |
2019年 | 3560篇 |
2018年 | 8946篇 |
2017年 | 8398篇 |
2016年 | 9596篇 |
2015年 | 9815篇 |
2014年 | 17389篇 |
2013年 | 18028篇 |
2012年 | 9212篇 |
2011年 | 9198篇 |
2010年 | 12159篇 |
2009年 | 15883篇 |
2008年 | 8721篇 |
2007年 | 6868篇 |
2006年 | 9060篇 |
2005年 | 6309篇 |
2004年 | 5148篇 |
2003年 | 3896篇 |
2002年 | 3760篇 |
2001年 | 3990篇 |
2000年 | 3144篇 |
1999年 | 3415篇 |
1998年 | 3906篇 |
1997年 | 3662篇 |
1996年 | 3542篇 |
1995年 | 3368篇 |
1994年 | 2079篇 |
1993年 | 1675篇 |
1992年 | 1463篇 |
1991年 | 1485篇 |
1990年 | 1125篇 |
1989年 | 1225篇 |
1988年 | 1050篇 |
1987年 | 890篇 |
1986年 | 919篇 |
1985年 | 745篇 |
1984年 | 584篇 |
1983年 | 541篇 |
1982年 | 549篇 |
1981年 | 423篇 |
1980年 | 379篇 |
1979年 | 316篇 |
1978年 | 340篇 |
1977年 | 410篇 |
1975年 | 285篇 |
1972年 | 310篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
Susan M Domchek Andrea Eisen Kathleen Calzone Jill Stopfer Anne Blackwood Barbara L Weber 《Journal of clinical oncology》2003,21(4):593-601
Breast cancer risk assessment provides an estimation of disease risk that can be used to guide management for women at all levels of risk. In addition, the likelihood that breast cancer risk is due to specific genetic susceptibility (such as BRCA1 or BRCA2 mutations) can be determined. Recent developments have reinforced the clinical importance of breast cancer risk assessment. Tamoxifen chemoprevention as well as prevention studies such as the Study of Tamoxifen and Raloxifene are available to women at increased risk of developing breast cancer. In addition, specific management strategies are now defined for BRCA1 and BRCA2 mutation carriers. Risk may be assessed as the likelihood of developing breast cancer (using risk assessment models) or as the likelihood of detecting a BRCA1 or BRCA2 mutation (using prior probability models). Each of the models has advantages and disadvantages, and all need to be interpreted in context. We review available risk assessment tools and discuss their application. As illustrated by clinical examples, optimal counseling may require the use of several models, as well as clinical judgment, to provide the most accurate and useful information to women and their families. 相似文献
43.
44.
Andrea R Genazzani Hermann P G Schneider Nick Panay Esme A Nijland 《Gynecological endocrinology》2006,22(7):369-375
OBJECTIVES: To identify and describe current women's thoughts about the menopause, hormone treatment (HT) and perceptions about breast cancer. METHODS: Between December 2004 and January 2005, 4201 postmenopausal women in seven European countries were interviewed via a standardized computer-aided telephone interview protocol. RESULTS: Almost all women reported to have experienced climacteric symptoms, and 63% of the women rated them as being severe. Only 52% of women were aware of the benefits of HT for relief of climacteric symptoms. Although 84% felt that severe symptoms should be treated, only 40% had used HT at some point in time. Thirty-four percent of the women preferring treatment with natural products did so because of the risk of breast cancer associated with HT. HT was recognized by 59% of the women as one of the most important contributors to an increased breast cancer risk. Most women received their information about HT and breast cancer risk from the media. CONCLUSIONS: This European survey reveals that the majority of women experience climacteric symptoms but that their decision whether or not to use HT is highly dependent on their concern about breast cancer risk. An increase in knowledge of the benefits and risks of HT is required for women to make appropriate decisions about hormone use. 相似文献
45.
Prostatitis and male infertility are frequent disorders, and the role of prostatitis in male infertility has been under discussion for more than 30 years. Many researchers have shown relevant links between the two. Although a causal relationship has not been definitely demonstrated, increasing evidence shows that chronic prostatitis has a relevant negative impact on male fertility potential, at least in certain subgroups. In the following review, we focus on the present state of knowledge on the role of chronic prostatitis as an etiologic factor in male infertility. 相似文献
46.
J. Curtis Nickel MD 《Current Prostate Reports》2006,4(3):132-137
Medical therapy is currently the most popular treatment choice for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Because medical therapy of BPH-related LUTS is considered a life-long strategy, short- and long-term cost considerations should play a major role in therapeutic decision-making. The effectiveness in terms of long and short amelioration of symptoms, flow rate, and quality of life are well documented for 5α-blockers and 5α-reductase inhibitors as well as for the gold standard treatment for BPH, transurethral resection of the prostate and minimally invasive therapies. Short-and long-term safety concerns also are well documented for these various treatment options. On the contrary, short- and long-term costs have been less well studied and comparisons depend on the model or analyses undertaken in the few studies available. However, the economic studies based on prospective clinical trial data that have become available throughout the past several decades allow us to rationalize our use of α-blockers, 5α -reductase inhibitors, and combination therapy, taking into consideration age, severity of symptoms, prostate volume, prostate-specific antigen, and the differential response of the various medications (and combination) in selected patients. Based on current studies, 5α -blockers generally provide cost-effective therapy for most patients, whereas 5α-reductase therapy and combination therapy provide cost-effective treatment for patients with larger prostate glands or higher baseline prostate-specific antigen levels. 相似文献
47.
48.
INTRODUCTION: The clinical presentation of morphea varies from localized plaques to generalized eruptions. Its cause remains unknown and medical treatments have often proved unsatisfactory. Studies have previously shown that improvement of hypertrophic scars and fibrotic skin can be achieved with the use of a 585 nm pulsed dye laser (PDL). METHODS: A case of plaque-type morphea was treated with 585 nm pulsed dye laser irradiation at an average fluence of 5.0 J/cm2 at bimonthly time intervals. RESULTS: Marked clinical improvement as evidenced by improved pliability and skin coloration was seen after 4 successive PDL treatments. No side effects or complications were encountered. CONCLUSION: Pulsed dye laser therapy is a viable treatment option for morphea. The mechanism of its effect in this condition remains unknown. 相似文献
49.
Angiotensin Converting Enzyme Inhibitors: Animal Experiments Suggest a New Pharmacological Treatment for Alcohol Abuse in Humans 总被引:1,自引:0,他引:1
G. Spinosa MSc E. Perlanski Dipl Tech. F. H. H. Leenen MD R. B. Stewart MSc L. A. Grupp DSc 《Alcoholism, clinical and experimental research》1988,12(1):65-70
The prevalence of heavy alcohol consumption is a major problem of increasing proportions throughout the world. Although alcohol sensitizing drugs and more recently serotonin uptake inhibitors are drug interventions with some following, their long term beneficial consequences have yet to be demonstrated. In recent years, we have demonstrated that manipulating activity in the renin-angiotensin system will dramatically alter voluntary alcohol consumption in rats. Based on these findings, the present study evaluated the ability of a class of drugs known as the angiotensin converting enzyme inhibitors to reduce voluntary alcohol drinking in laboratory animals. These drugs prevent the conversion of angiotensin I to angiotensin II. They have been licensed for use in Europe and North America and are indicated in the treatment of hypertension. Our experiments showed that both captopril (Capoten, Squibb) and enalapril (Vasotec, Merck Sharpe & Dohme) can reduce alcohol drinking in both normotensive and hypertensive animals regardless of whether the pattern of intake is in a bout or of a less exaggerated nature. Furthermore, this change in alcohol intake can occur without concomitant changes in blood pressure, plasma renin activity, overall fluid balance, or the distribution and metabolism of alcohol. Taken together these findings suggest that the angiotensin converting enzyme inhibitors should be evaluated in a clinical setting for they may prove to be a useful new treatment or treatment adjunct for alcohol abuse in humans. 相似文献
50.